NCT04045743View on ClinicalTrials.gov

The Benefit of Bermekimab in Patients With Systemic Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 19, 2019

Primary Completion Date

January 7, 2021

Study Completion Date

July 19, 2021

Conditions
Scleroderma, Systemic
Interventions
DRUG

MABp1 (Bermekimab) OR Placebo

Period A: patients randomized 1:1 to weekly subcutaneous treatment with 400mg Bermekimab or matched Placebo for 12 weeks

DRUG

MABp1 (Bermekimab)

Period B: all patients treated weekly with subcutaneous 400mg Bermekimab for 12 weeks

Trial Locations (2)

11527

Department of Pathophysiology, LAIKO Athens General Hospital, Athens

12462

4th Department of Internal Medicine, ATTIKON University Hospital, Athens

All Listed Sponsors
lead

Hellenic Institute for the Study of Sepsis

OTHER

NCT04045743 - The Benefit of Bermekimab in Patients With Systemic Sclerosis | Biotech Hunter | Biotech Hunter